Targets › SLC12A1
20 programs from 17 companies in 21 trials: 11 Phase 4, 5 Phase 3, 3 Phase 1, 2 Phase 2; Cardiovascular, Oncology, Genitourinary; next expected readout Nov 2026.
Renal sodium, potassium and chloride non-electrogenic ion symporter that mediates the transepithelial NaCl reabsorption in the thick ascending limb and plays an essential role in the urinary concentration and volume regulation. It can substitute NH4(+) for K(+), enabling NH4(+) apical transmembrane transport in the medullary thick ascending limb (MTAL). (UniProt, Q13621)
Open in Phaseline: the race on SLC12A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Heart Center Research, LLC | Bumetanide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Heart Failure, Congestive | Dec 2026 |
| Heart Center Research, LLC | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Heart Failure, Congestive | Dec 2026 |
| Heart Center Research, LLC | Torsemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Heart Failure, Congestive | Dec 2026 |
| Morten H. Bestle | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Fluid Overload | Apr 2027 |
| Copenhagen University Hospital, Rigshospitalet | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Pulmonary Edema | May 2027 |
| Lakeland Regional Health Systems, Inc. | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Heart Failure | Jun 2027 |
| University of Aarhus | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Acute Heart Failure | Sep 2027 |
| University of Delaware | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Salt-Sensitivity of Blood Pressure | Jan 2028 |
| University of California, Irvine | furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Preeclampsia | Jun 2028 |
| Chiang Mai University | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 4 | Acute Kidney Injury | Dec 2028 |
| Instituto de Investigación Sanitaria Aragón | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 3 | Acute Heart Failure | Nov 2026 |
| Stacy Johnson | Bumetanide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 3 | Cirrhosis | Mar 2029 |
| Sherief Abd-Elsalam | Bumetanide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 3 | Autism | Dec 2030 |
| Northwestern University | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 3 | BPH With Urinary Obstruction | – |
| University Hospital, Tours | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 3 | Kidney Stone | – |
| Stanford University | Bumetanide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 2 | Alzheimer Disease | Dec 2026 |
| Emory University | Furosemide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 2 | Prostate Adenocarcinoma | Jul 2028 |
| Memorial Sloan Kettering Cancer Center | Bumetanide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 1 | Unresectable Hepatocellular Carcinoma | Apr 2027 |
| Yale University | Bumetanide Sodium-(potassium)-chloride cotransporter 2 inhibitor | SLC12A1 | Phase 1 | Heart Failure | May 2027 |
| Yale University | Bendroflumethiazide Thiazide diuretic | SLC12A1 | Phase 1 | Heart Failure | Jun 2028 |
Heart Failure (3) Heart Failure, Congestive (3) Acute Heart Failure (3) Fluid Overload (1) Salt-Sensitivity of Blood Pressure (1) Unresectable Hepatocellular Carcinoma (1) BPH With Urinary Obstruction (1) Alzheimer Disease (1) Kidney Stone (1) Acute Kidney Injury (1) Preeclampsia (1) Autism (1)
small molecule (20)
Heart Center Research, LLC (3) Yale University (2) Morten H. Bestle (1) University of Delaware (1) Lakeland Regional Health Systems, Inc. (1) Memorial Sloan Kettering Cancer Center (1) Northwestern University (1) Instituto de Investigación Sanitaria Aragón (1) University of Aarhus (1) Stanford University (1) University Hospital, Tours (1) Chiang Mai University (1) University of California, Irvine (1) Sherief Abd-Elsalam (1) Copenhagen University Hospital, Rigshospitalet (1) Stacy Johnson (1) Emory University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.